Researchers recently assessed the clinical activity of L-Grb2–based therapeutic BP1001 (Bio-Path Holdings, Inc.)in patients with refractory or relapsed acute myeloid leukemia in a phase 1 trial. The gene discussed is GRB2; the disease is acute myeloid leukemia.